• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Immune Netw . Conserved Influenza Epitopes Delivered via MHC-I-Functionalized Nanocarriers Induce Influenza-Specific CTL Responses

tetano

Editor, Senior Moderator
Immune Netw

. 2026 Jul 30;26(4):e30.
doi: 10.4110/in.2026.26.e30. eCollection 2026 Aug.

Conserved Influenza Epitopes Delivered via MHC-I-Functionalized Nanocarriers Induce Influenza-Specific CTL Responses​


Sang-Hyun Kim 1 , Bill Thaddeus Padasas 1 2 , Dong-Su Kim 3 , Doo-Jin Kim 4 , Jeong-Ki Kim 1 2

Affiliations


Abstract​


Seasonal influenza evades vaccine-induced immunity via ongoing antigenic drift, highlighting the critical necessity for universal vaccines that elicit broadly cross-reactive CD8+ T cell responses targeting conserved internal viral epitopes. In pursuit of this objective, we prepared biocompatible and biodegradable poly(lactic-co-glycolic acid) (PLGA) nanocarriers (NCs) and functionalized them with MHC-I molecules. Among various murine and human epitopes tested, PB1703-711 and M158-66 showed the highest stabilization of H-2Kb and HLA-A2.1 molecules, respectively, thereby promoting sustained Ag presentation. These NCs exhibited specific peptide-loading onto MHC-I molecules while minimizing non-specific peptide surface binding. In vivo immunization of C57BL/6 mice with PB1703-711-loaded NCs elicited epitope-specific CD8+ T cell responses. Furthermore, the successful specific peptide-loading of HLA-A2.1-attached NCs highlighted the system's human translational applicability. Ultimately, by combining effective Ag delivery with specific CTL induction, this designed NC platform provides a promising strategy for developing next-generation universal vaccines.

Keywords: Cytotoxic T lymphocytes; Influenza virus; PLGA nanocarrier; Peptides; Universal influenza vaccine.
 
Back
Top Bottom